Polymorphisms in drug metabolism genes, smoking, and p53 mutations in breast cancer

Beth O. Van Emburgh, Jennifer Hu, Edward A. Levine, Libyadda J. Mosley, L. Douglas Case, Hui Yi Lin, Sommer N. Knight, Nancy D. Perrier, Peter Rubin, Gary B. Sherrill, Cindy S. Shaw, Lisa A. Carey, Lynda R. Sawyer, Glenn O. Allen, Clara Milikowski, Mark C. Willingham, Mark Steven Miller

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

Polymorphisms in phase I and phase II enzymes may enhance the occurrence of mutations at critical tumor suppressor genes, such as p53, and increase breast cancer risk by either increasing the activation or detoxification of carcinogens and/or endogenous estrogens. We analyzed polymorphisms in CYP1B1, GSTM1, GSTT1, and GSTP1 and p53 mutations in 323 breast tumor samples. Approximately 11% of patients exhibited mutations in p53. Women with mutations had a significantly younger age of diagnosis (P = 0.01) and a greater incidence of tumors classified as stage II or higher (P = 0.002). More women with mutations had a history of smoking (55%) compared to women without mutations (39%). Although none of the genotypes alone were associated with p53 mutations, positive smoking history was associated with p53 mutations in women with the GSTM1 null allele [OR = 3.54; 95% CI = 0.97-12.90 P = 0.06] compared to women with the wild-type genotype and smoking history [OR = 0.62, 95% CI = 0.19-2.07], although this association did not reach statistical significance. To test for gene-gene interactions, our exploratory analysis in the Caucasian cases suggested that individuals with the combined GSTP1 105 VV, CYP1B1 432 LV/VV, and GSTM1 positive genotype were more likely to harbor mutations in p53 [OR = 4.94; 95% CI = 1.11-22.06]. Our results suggest that gene-smoking and gene-gene interactions may impact the prevalence of p53 mutations in breast tumors. Elucidating the etiology of breast cancer as a consequence of common genetic polymorphisms and the genotoxic effects of smoking will enable us to improve the design of prevention strategies, such as lifestyle modifications, in genetically susceptible subpopulations.

Original languageEnglish
Pages (from-to)88-99
Number of pages12
JournalMolecular Carcinogenesis
Volume47
Issue number2
DOIs
StatePublished - Feb 1 2008

Fingerprint

p53 Genes
Smoking
Breast Neoplasms
Mutation
Pharmaceutical Preparations
Genes
Genotype
History
Genetic Polymorphisms
Tumor Suppressor Genes
Carcinogens
Life Style
Estrogens
Alleles
Incidence

Keywords

  • Breast cancer
  • Drug metabolism
  • p53
  • Polymorphisms

ASJC Scopus subject areas

  • Cancer Research
  • Molecular Biology

Cite this

Van Emburgh, B. O., Hu, J., Levine, E. A., Mosley, L. J., Case, L. D., Lin, H. Y., ... Miller, M. S. (2008). Polymorphisms in drug metabolism genes, smoking, and p53 mutations in breast cancer. Molecular Carcinogenesis, 47(2), 88-99. https://doi.org/10.1002/mc.20365

Polymorphisms in drug metabolism genes, smoking, and p53 mutations in breast cancer. / Van Emburgh, Beth O.; Hu, Jennifer; Levine, Edward A.; Mosley, Libyadda J.; Case, L. Douglas; Lin, Hui Yi; Knight, Sommer N.; Perrier, Nancy D.; Rubin, Peter; Sherrill, Gary B.; Shaw, Cindy S.; Carey, Lisa A.; Sawyer, Lynda R.; Allen, Glenn O.; Milikowski, Clara; Willingham, Mark C.; Miller, Mark Steven.

In: Molecular Carcinogenesis, Vol. 47, No. 2, 01.02.2008, p. 88-99.

Research output: Contribution to journalArticle

Van Emburgh, BO, Hu, J, Levine, EA, Mosley, LJ, Case, LD, Lin, HY, Knight, SN, Perrier, ND, Rubin, P, Sherrill, GB, Shaw, CS, Carey, LA, Sawyer, LR, Allen, GO, Milikowski, C, Willingham, MC & Miller, MS 2008, 'Polymorphisms in drug metabolism genes, smoking, and p53 mutations in breast cancer', Molecular Carcinogenesis, vol. 47, no. 2, pp. 88-99. https://doi.org/10.1002/mc.20365
Van Emburgh, Beth O. ; Hu, Jennifer ; Levine, Edward A. ; Mosley, Libyadda J. ; Case, L. Douglas ; Lin, Hui Yi ; Knight, Sommer N. ; Perrier, Nancy D. ; Rubin, Peter ; Sherrill, Gary B. ; Shaw, Cindy S. ; Carey, Lisa A. ; Sawyer, Lynda R. ; Allen, Glenn O. ; Milikowski, Clara ; Willingham, Mark C. ; Miller, Mark Steven. / Polymorphisms in drug metabolism genes, smoking, and p53 mutations in breast cancer. In: Molecular Carcinogenesis. 2008 ; Vol. 47, No. 2. pp. 88-99.
@article{aadf83e888f74c37b86733bcc78bef54,
title = "Polymorphisms in drug metabolism genes, smoking, and p53 mutations in breast cancer",
abstract = "Polymorphisms in phase I and phase II enzymes may enhance the occurrence of mutations at critical tumor suppressor genes, such as p53, and increase breast cancer risk by either increasing the activation or detoxification of carcinogens and/or endogenous estrogens. We analyzed polymorphisms in CYP1B1, GSTM1, GSTT1, and GSTP1 and p53 mutations in 323 breast tumor samples. Approximately 11{\%} of patients exhibited mutations in p53. Women with mutations had a significantly younger age of diagnosis (P = 0.01) and a greater incidence of tumors classified as stage II or higher (P = 0.002). More women with mutations had a history of smoking (55{\%}) compared to women without mutations (39{\%}). Although none of the genotypes alone were associated with p53 mutations, positive smoking history was associated with p53 mutations in women with the GSTM1 null allele [OR = 3.54; 95{\%} CI = 0.97-12.90 P = 0.06] compared to women with the wild-type genotype and smoking history [OR = 0.62, 95{\%} CI = 0.19-2.07], although this association did not reach statistical significance. To test for gene-gene interactions, our exploratory analysis in the Caucasian cases suggested that individuals with the combined GSTP1 105 VV, CYP1B1 432 LV/VV, and GSTM1 positive genotype were more likely to harbor mutations in p53 [OR = 4.94; 95{\%} CI = 1.11-22.06]. Our results suggest that gene-smoking and gene-gene interactions may impact the prevalence of p53 mutations in breast tumors. Elucidating the etiology of breast cancer as a consequence of common genetic polymorphisms and the genotoxic effects of smoking will enable us to improve the design of prevention strategies, such as lifestyle modifications, in genetically susceptible subpopulations.",
keywords = "Breast cancer, Drug metabolism, p53, Polymorphisms",
author = "{Van Emburgh}, {Beth O.} and Jennifer Hu and Levine, {Edward A.} and Mosley, {Libyadda J.} and Case, {L. Douglas} and Lin, {Hui Yi} and Knight, {Sommer N.} and Perrier, {Nancy D.} and Peter Rubin and Sherrill, {Gary B.} and Shaw, {Cindy S.} and Carey, {Lisa A.} and Sawyer, {Lynda R.} and Allen, {Glenn O.} and Clara Milikowski and Willingham, {Mark C.} and Miller, {Mark Steven}",
year = "2008",
month = "2",
day = "1",
doi = "10.1002/mc.20365",
language = "English",
volume = "47",
pages = "88--99",
journal = "Molecular Carcinogenesis",
issn = "0899-1987",
publisher = "Wiley-Liss Inc.",
number = "2",

}

TY - JOUR

T1 - Polymorphisms in drug metabolism genes, smoking, and p53 mutations in breast cancer

AU - Van Emburgh, Beth O.

AU - Hu, Jennifer

AU - Levine, Edward A.

AU - Mosley, Libyadda J.

AU - Case, L. Douglas

AU - Lin, Hui Yi

AU - Knight, Sommer N.

AU - Perrier, Nancy D.

AU - Rubin, Peter

AU - Sherrill, Gary B.

AU - Shaw, Cindy S.

AU - Carey, Lisa A.

AU - Sawyer, Lynda R.

AU - Allen, Glenn O.

AU - Milikowski, Clara

AU - Willingham, Mark C.

AU - Miller, Mark Steven

PY - 2008/2/1

Y1 - 2008/2/1

N2 - Polymorphisms in phase I and phase II enzymes may enhance the occurrence of mutations at critical tumor suppressor genes, such as p53, and increase breast cancer risk by either increasing the activation or detoxification of carcinogens and/or endogenous estrogens. We analyzed polymorphisms in CYP1B1, GSTM1, GSTT1, and GSTP1 and p53 mutations in 323 breast tumor samples. Approximately 11% of patients exhibited mutations in p53. Women with mutations had a significantly younger age of diagnosis (P = 0.01) and a greater incidence of tumors classified as stage II or higher (P = 0.002). More women with mutations had a history of smoking (55%) compared to women without mutations (39%). Although none of the genotypes alone were associated with p53 mutations, positive smoking history was associated with p53 mutations in women with the GSTM1 null allele [OR = 3.54; 95% CI = 0.97-12.90 P = 0.06] compared to women with the wild-type genotype and smoking history [OR = 0.62, 95% CI = 0.19-2.07], although this association did not reach statistical significance. To test for gene-gene interactions, our exploratory analysis in the Caucasian cases suggested that individuals with the combined GSTP1 105 VV, CYP1B1 432 LV/VV, and GSTM1 positive genotype were more likely to harbor mutations in p53 [OR = 4.94; 95% CI = 1.11-22.06]. Our results suggest that gene-smoking and gene-gene interactions may impact the prevalence of p53 mutations in breast tumors. Elucidating the etiology of breast cancer as a consequence of common genetic polymorphisms and the genotoxic effects of smoking will enable us to improve the design of prevention strategies, such as lifestyle modifications, in genetically susceptible subpopulations.

AB - Polymorphisms in phase I and phase II enzymes may enhance the occurrence of mutations at critical tumor suppressor genes, such as p53, and increase breast cancer risk by either increasing the activation or detoxification of carcinogens and/or endogenous estrogens. We analyzed polymorphisms in CYP1B1, GSTM1, GSTT1, and GSTP1 and p53 mutations in 323 breast tumor samples. Approximately 11% of patients exhibited mutations in p53. Women with mutations had a significantly younger age of diagnosis (P = 0.01) and a greater incidence of tumors classified as stage II or higher (P = 0.002). More women with mutations had a history of smoking (55%) compared to women without mutations (39%). Although none of the genotypes alone were associated with p53 mutations, positive smoking history was associated with p53 mutations in women with the GSTM1 null allele [OR = 3.54; 95% CI = 0.97-12.90 P = 0.06] compared to women with the wild-type genotype and smoking history [OR = 0.62, 95% CI = 0.19-2.07], although this association did not reach statistical significance. To test for gene-gene interactions, our exploratory analysis in the Caucasian cases suggested that individuals with the combined GSTP1 105 VV, CYP1B1 432 LV/VV, and GSTM1 positive genotype were more likely to harbor mutations in p53 [OR = 4.94; 95% CI = 1.11-22.06]. Our results suggest that gene-smoking and gene-gene interactions may impact the prevalence of p53 mutations in breast tumors. Elucidating the etiology of breast cancer as a consequence of common genetic polymorphisms and the genotoxic effects of smoking will enable us to improve the design of prevention strategies, such as lifestyle modifications, in genetically susceptible subpopulations.

KW - Breast cancer

KW - Drug metabolism

KW - p53

KW - Polymorphisms

UR - http://www.scopus.com/inward/record.url?scp=38949097138&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=38949097138&partnerID=8YFLogxK

U2 - 10.1002/mc.20365

DO - 10.1002/mc.20365

M3 - Article

C2 - 17683074

AN - SCOPUS:38949097138

VL - 47

SP - 88

EP - 99

JO - Molecular Carcinogenesis

JF - Molecular Carcinogenesis

SN - 0899-1987

IS - 2

ER -